Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Jiangsu Ambition In-licenses Prostate Treatment from Sweden's Lidds

publication date: May 16, 2018

Jiangsu Ambition Medical has in-licensed China rights to a prostate treatment that is delivered via an injected depot system, which administers the drug directly to the tumor for up to six months. Sweden's Lidds AB developed Liproca® Depot and is currently conducting a Phase IIb trial in Finland and Canada. Ambition will pay $1 million upfront, plus milestones and royalties for China rights. It will also be responsible for securing China regulatory approval, which may be the first approval for Liproca globally. More details....

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China